In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt plc

http://www.mallinckrodt.com

Latest From Mallinckrodt plc

Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline

The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.

Financing Platform Technologies

US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development

Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.

Approvals Review Pathway

Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery

The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.

Financing Innovation

Merck’s Welireg Gets Orphan Pricing Ahead Of Broader RCC Indications

The company set a $26,400 per month list price for the HIF-2α inhibitor in its first US FDA-approved indication of VHL disease-associated tumors, but the drug is being studied in broader populations.

Launches Pricing Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aspect Medical Systems, Inc.
    • BÂRRX Medical, Inc.
    • Cadence Pharmaceuticals, Inc.
    • CNS Therapeutics, Inc.
    • ev3 Inc.
    • Given Imaging Ltd.
    • Ikaria Holdings, Inc.
    • InfaCare Pharmaceutical Corporation
    • INO Therapeutics, LLC
    • Mallinckrodt Inc.
    • Mallinckrodt Pharmaceuticals
    • Micro Therapeutics, Inc.
    • Nellcor Puritan Bennett, Inc.
    • Ocera Therapeutics Inc. (OCRX)
    • Oridion Systems Ltd.
    • Questcor Pharmaceuticals, Inc.
    • Somanetics Corp.
    • Sonorant Inc.
    • SpecGx Inc.
    • Sucampo Pharmaceuticals, Inc.(SCMP)
    • VNUS Medical Technologies
    • Stratatech Corporation
    • Tranzyme Pharma
UsernamePublicRestriction

Register